---
title: "Tremfya (guselkumab) in plaque psoriasis: Safety questions"
description: "Safety questions on Tremfya (guselkumab) in plaque psoriasis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Side effects, Safety evidence, and Warnings. Questions: What are the most common side effects of Tremfya for plaque psoriasis? What are the long-term side effects of Tremfya for plaque psoriasis? Does Tremfya cause antidrug antibodies in plaque psoriasis? Can Tremfya cause liver problems in plaque psoriasis? 4 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis/safety"
published: "2026-11-13T03:43:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Tremfya (guselkumab) in plaque psoriasis: Safety questions

Manufacturer: Janssen Biotech, Inc.  
Prescribing information: [Tremfya](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf)

Safety questions that apply to every indication of Tremfya are on [Tremfya (guselkumab), all indications: Safety](https://www.evicenter.com/medical-information/tremfya/safety).

## Side effects

<a id="tremfya-side-effects"></a>

### What are the most common side effects of Tremfya for plaque psoriasis?

Applies to: Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

> “In the 16-week placebo-controlled period of the pooled clinical trials (PsO1 
> and PsO2), adverse events occurred in 49% of subjects in the TREMFYA group 
> compared to 47% of subjects in the placebo group and 49% of subjects in the U.S. 
> licensed adalimumab group. Serious adverse events occurred in 1.9% of subjects 
> in the TREMFYA group (6.3 events per 100 patient-years of follow-up) compared to 
> 1.4% of subjects in the placebo group (4.7 events per 100 patient-years of follow-
> up), and in 2.6% of subjects in U.S. licensed adalimumab group (9.9 events per 
> 100 patient-years of follow-up).”

Source: [TREMFYA: Prescribing information, page 3, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf#page=3)

> “Adverse Reactions Occurring in ≥1% of Adult Subjects with Moderate-to-
> Severe Plaque Psoriasis through Week 16 in Trials PsO1 and PsO2
> TREMFYA<sup>a</sup>
> 100 mg
> N=823
> n (%)
> Adalimumab<sup>b</sup>
> N=196
> n (%)
> Placebo
> N=422
> n (%)
> Upper respiratory infections<sup>c</sup>
> 118 (14.3)
> 21 (10.7)
> 54 (12.8)
> Headache<sup>d</sup>
> 38 (4.6)
> 2 (1.0)
> 14 (3.3)
> Injection site reactions<sup>e</sup>
> 37 (4.5)
> 15 (7.7)
> 12 (2.8)
> Arthralgia
> 22 (2.7)
> 4 (2.0)
> 9 (2.1)
> Diarrhea
> 13 (1.6)
> 3 (1.5)
> 4 (0.9)
> Gastroenteritis<sup>f</sup>
> 11 (1.3)
> 4 (2.0)
> 4 (0.9)
> Tinea infections<sup>g</sup>
> 9 (1.1)
> 0
> 0
> Herpes simplex infections<sup>h</sup>
> 9 (1.1)
> 0
> 2 (0.5)
> <sup>a</sup>	Subjects receiving 100 mg of TREMFYA at Week 0, Week 4, and every 8 weeks 
> thereafter
> <sup>b</sup>	U.S. licensed adalimumab
> <sup>c</sup>	Upper respiratory infections include nasopharyngitis, upper respiratory tract 
> infection (URTI), pharyngitis, and viral URTI.
> <sup>d</sup>	Headache includes headache and tension headache.
> <sup>e</sup>	Injection site reactions include injection site erythema, bruising, hematoma, 
> hemorrhage, swelling, edema, pruritus, pain, discoloration, induration, inflammation, 
> and urticaria.
> <sup>f</sup>	 Gastroenteritis includes gastroenteritis and viral gastroenteritis.
> <sup>g</sup>	Tinea infections include tinea pedis, tinea cruris, tinea infection, and tinea 
> manuum infections.
> <sup>h</sup>	Herpes simplex infections include oral herpes, herpes simplex, genital herpes, 
> genital herpes simplex, and nasal herpes simplex.”

Source: [TREMFYA: Prescribing information, page 3, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf#page=3)

> “Adverse reactions that occurred in < 1% but > 0.1% of subjects in the TREMFYA 
> group and at a higher rate than in the placebo group through Week 16 in trials PsO1 
> and PsO2 were migraine, candida infections, and urticaria.”

Source: [TREMFYA: Prescribing information, page 3, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf#page=3)

<a id="tremfya-antidrug-antibodies"></a>

### Does Tremfya cause antidrug antibodies in plaque psoriasis?

> “The observed incidence of anti-drug antibodies is highly dependent on the 
> sensitivity and specificity of the assay. Differences in assay methods preclude 
> meaningful comparisons of the incidence of anti-drug antibodies in the studies 
> described below with the incidence of anti-drug antibodies in other studies, 
> including those of guselkumab or of other guselkumab products.”

Source: [TREMFYA: Prescribing information, page 7, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf#page=7)

> “Up to Week 52, approximately 6% of adult subjects treated with TREMFYA 
> developed antidrug antibodies. Of the subjects who developed antidrug antibodies, 
> approximately 7% had antibodies that were classified as neutralizing antibodies. 
> Among the 46 subjects who developed antibodies to guselkumab and had evaluable 
> data, 21 subjects exhibited lower trough levels of guselkumab, including one subjects 
> who experienced loss of efficacy after developing high antibody titers. Up to Week 
> 156, approximately 9% of subjects treated with TREMFYA developed antidrug 
> antibodies and of these subjects approximately 6% were classified as neutralizing 
> antibodies. However, antibodies to guselkumab were generally not associated with 
> changes in clinical response or development of injection-site reactions.”

Source: [TREMFYA: Prescribing information, page 7, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf#page=7)

> “Up to Week 44, 18% (n=21/114) of pediatric subjects 6 years of age and older treated 
> with TREMFYA developed anti-drug antibodies, none of the anti-drug antibodies 
> were classified as neutralizing. The development of antibodies to guselkumab 
> did not impact the pharmacokinetics of guselkumab and was not associated with 
> changes in clinical response or development of injection-site reactions. However, 
> the small number of subjects who were positive for antibodies to guselkumab limits 
> definitive conclusions.”

Source: [TREMFYA: Prescribing information, page 7, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf#page=7)

## Safety evidence

<a id="tremfya-long-term-side-effects"></a>

### What are the long-term side effects of Tremfya for plaque psoriasis?

Applies to: Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

> “Through Week 48, no new adverse reactions were identified with TREMFYA 
> use and the frequency of the adverse reactions was similar to the safety 
> profile observed during the first 16 weeks of treatment.”

Source: [TREMFYA: Prescribing information, page 3, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf#page=3)

> “No new safety signals were reported in VISIBLE through Week 48”

Source: [TREMFYA: Safety In Plaque PsO & Active PsA, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/safety/#:~:text=No%20new%20safety%20signals%20were%20reported%20in%20VISIBLE%20through%20Week%2048)

Note: The quoted statements cover treatment through Week 48.

## Warnings

<a id="tremfya-liver"></a>

### Can Tremfya cause liver problems in plaque psoriasis?

> “In patients with plaque psoriasis or psoriatic arthritis, if clinically indicated, evaluate liver enzymes and bilirubin at baseline, and periodically thereafter according to routine patient management.
>
> Consider other treatment options in patients with evidence of acute liver disease or cirrhosis. Prompt investigation of the cause of liver enzyme elevation is recommended to identify potential cases of drug-induced liver injury. Interrupt treatment if drug-induced liver injury is suspected, until this diagnosis is excluded. Instruct patients to seek immediate medical attention if they experience symptoms suggestive of hepatic dysfunction.”

Source: [TREMFYA: Moderate To Severe Plaque PsO, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/#:~:text=In%20patients%20with%20plaque%20psoriasis,symptoms%20suggestive%20of%20hepatic%20dysfunction.)

> “Elevated liver enzymes were reported more frequently in the TREMFYA 
> group (2.6%) than in the placebo group (1.9%). Of the 21 subjects who were 
> reported to have elevated liver enzymes in the TREMFYA group, all events 
> except one were mild to moderate in severity and none of the events led to 
> discontinuation of TREMFYA.”

Source: [TREMFYA: Prescribing information, page 3, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf#page=3)

## Related pages
- [Medical information: Tremfya (guselkumab): Plaque psoriasis](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis)
- [Indication](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis/clinical-trials)
- [Specific populations](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis/guidelines)
